Building on our industry-first latex technology, we provide in vitro diagnostic reagents and clinical laboratory instruments and contribute to the advancement of healthcare through highly accurate and reliable diagnostic data.

As the healthcare environment evolves and the role of diagnostic testing continues to diversify, we are expanding our diagnostic solutions centered on the development of high-performance reagents. These solutions include clinical laboratory instruments and point-of-care testing (POCT) products designed to address a wide range of needs in medical settings. Through continuous technological innovation and product development, we support healthcare professionals with reliable diagnostic solutions.

Looking ahead, we will leverage the knowledge and technologies we have cultivated in the coagulation and fibrinolysis fields to further advance our research and development activities. In particular, we will focus on the cardiovascular field related to assessing the risk of complications associated with various diseases, including cancer. By strengthening and expanding our reagent business while advancing our core technologies—reagent development technologies, biosensing technologies, and the integration of reagents with clinical laboratory instruments—we aim to create new diagnostic value.

Our Strength

Based on our proprietary technology development centered on reagents, we deliver highly reliable diagnostic solutions to healthcare providers through product design driven by market needs and precision manufacturing that ensures high quality.

Our History

Since launching Japan’s first serum transaminase (GOT/GPT) measurement reagent in 1962, we have contributed to the advancement of healthcare for decades as a leading company in the fields of medical devices and in vitro diagnostic products.

Following our carve-out from the Panasonic Group in 2014, we have continued to develop high-precision, highly reliable, and high-value-added products based on our strong development capabilities and manufacturing expertise. In November 2023, we further expanded our business foundation by succeeding to the diagnostics reagents and instruments business of LSI Medience Corporation, a subsidiary of PHC Holdings Corporation, through a company split. By inheriting the technologies and expertise cultivated over many years, we continue to strengthen and expand our in vitro diagnostics business.

See more